InvestSMART

Genetic Signatures Limited (ASX: GSS) - Share Price

- Current share price for GSS : $0.064

Genetic Signatures Limited (GSS), an ASX-listed company, is engaged in the research and development into identifying and commercialization of molecular diagnostics products to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces.

GSS General Information +

ASX Code GSS
Website http://www.geneticsignatures.com
Industry/Sector Life Sciences Tools & Services
Market Cap ($M) 14
GSS Share Price $0.064
Day High $0.068
Day Low $0.062
Last Close $0.064
GSS Share Price Movement - ( No change )
Prices as at 16:40, 10 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Genetic Signatures Limited (GSS) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Final 0.12¢ 0% 27 Aug 1996 30 Sep 1996 - - -

See all dividends from Genetic Signatures Limited (GSS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Genetic Signatures Limited (GSS) price-sensitive announcements

GSS - GSS responds to the BCAL Diagnostics Announcement
Genetic Signatures Limited, in response to BCAL Diagnostics' announcement about acquiring
Genetic Signatures Limited (GSS)
2 Jul 2026 | 2:41 PM
GSS - BDX: BCAL to Acquire Shares in Genetic Signatures
BCAL Diagnostics Limited announced their acquisition of 23,173,644 shares, equating to 10.
Genetic Signatures Limited (GSS)
2 Jul 2026 | 10:04 AM
GSS - Quarterly Activities/Appendix 4C Cash Flow Report
Genetic Signatures Limited reported $3 million in sales for Q3 FY2026, largely due to seas
Genetic Signatures Limited (GSS)
29 Apr 2026 | 8:22 AM
GSS - Danish Supply Agreement - Additional Information
Genetic Signatures Limited announced additional information regarding a Danish supply agre
Genetic Signatures Limited (GSS)
15 Apr 2026 | 4:37 PM

Genetic Signatures Limited (GSS) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 Becoming a substantial holder from BDX 2 Jul 2026 5:13PM $0.065 $0.064 fallen by 1.54%
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 GSS responds to the BCAL Diagnostics Announcement 2 Jul 2026 2:41PM $0.066 $0.064 fallen by 3.03%
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 BDX: BCAL to Acquire Shares in Genetic Signatures 2 Jul 2026 10:04AM $0.068 $0.064 fallen by 5.88%
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 Ceasing to be a substantial holder 1 Jul 2026 12:20PM $0.067 $0.064 fallen by 4.48%
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 Change of Company Secretary 19 Jun 2026 8:58AM $0.067 $0.064 fallen by 4.48%
Genetic Signatures Limited (GSS)
ORDINARY FULLY PAID
 Health Care $15 Change in substantial holding 18 Jun 2026 4:55PM $0.067 $0.064 fallen by 4.48%

GSS Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$12.73 -$5.60 -48.00% 0.00 0.00 0.00% 0.0%
2024A -$17.86 -$10.80 13.00% 0.00 0.00 0.00% 0.0%
2023A -$14.05 -$9.60 -564.60% 0.00 0.00 0.00% 0.0%

GSS Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Genetic Signatures Limited (GSS) $15M -0.4801 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

GSS Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.29 0.00
Market 0.28 13.10 1.15 0.59
Sector 0.44 27.80 2.51 1.90

GSS Directors

Name Position Start Date
Mr Michael Anton Aicher Executive Director - US Operations 16 May 2014
Dr Jenny Lee Harry Non-Executive Director 1 Oct 2024
Ms Anne Nicole Lockwood Non-Executive Director 1 Oct 2024
Ms Caroline Waldron Non-Executive Director, Non-Executive Chairman 13 May 2022

Genetic Signatures Limited (GSS) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
16 Dec 2024 AICHER, Michael Issued Direct Shares 66,666 $0.750 $49,999.500
8 Jul 2024 CHATONSKY, Stephane Issued Indirect Shares 27,750 $0.750 $20,812.500
8 Jul 2024 WALDRON, Caroline Issued Direct Shares 3,302 $0.750 $2,476.500

See all changes in directors' interest & trades for Genetic Signatures Limited (GSS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

GSS Management

Name Position
Allison Rossiter --
Sonya Tissera-Isaacs Company Secretary

GSS Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Genetic Signatures Limited (GSS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
44,949,035 (19.79%) Asian Union Investment Pty Limited
33,476,488 (14.74%) Perennial Value Management Limited
20,138,177 (8.87%) Regal Funds Management Pty Ltd
18,341,646 (8.08%) FIL Limited and the entities

GSS Calendar of Events

Date Event
25 February 2027 Report (Interim)
24 August 2026 Report (Annual)
24 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.